Showing results (41-50 of 51) with videos related to
Sort By:
Pageof 6
BMC Cancer|August 7, 2019
Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing studyMilena Casula, Panagiotis Paliogiannis, Fabrizio Ayala, et al.European Journal of Cancer (Oxford, England : 1990)|October 24, 2006
Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South ItalyMilena Casula, Maria Colombino, Maria P Satta, et al.International Journal of Molecular Sciences|July 20, 2021
The Enigmatic Role of TP53 in Germ Cell Tumours: Are We Missing Something?Margaret Ottaviano, Emilio Francesco Giunta, Pasquale Rescigno, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2012
BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanomaMaria Colombino, Mariaelena Capone, Amelia Lissia, et al.Frontiers in Oncology|May 9, 2022
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer PatientsStefano Mariani, Marco Puzzoni, Riccardo Giampieri, et al.Journal of Clinical Medicine|October 5, 2019
BRAF Mutations and Dysregulation of the MAP Kinase Pathway Associated to Sinonasal Mucosal MelanomasMaria Colombino, Panagiotis Paliogiannis, Antonio Cossu, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|June 19, 2023
BRAFV600 variant allele frequency predicts outcome in metastatic melanoma patients treated with BRAF and MEK inhibitorsMario Mandalà, Giuseppe Palmieri, Vienna Ludovini, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2004
BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup StudyMilena Casula, Maria Colombino, Maria P Satta, et al.Journal of Translational Medicine|October 15, 2016
Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based studyGrazia Palomba, Valentina Doneddu, Antonio Cossu, et al.NEJM Evidence|September 24, 2024
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in MelanomaPaolo A Ascierto, Mario Mandalà, Pier Francesco Ferrucci, et al.Pageof 6